17.97
price down icon1.64%   -0.30
after-market After Hours: 17.97
loading
Amylyx Pharmaceuticals Inc stock is traded at $17.97, with a volume of 1.36M. It is down -1.64% in the last 24 hours and up +34.91% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$18.27
Open:
$18.01
24h Volume:
1.36M
Relative Volume:
1.02
Market Cap:
$2.00B
Revenue:
$-665.00K
Net Income/Loss:
$-150.11M
P/E Ratio:
-11.92
EPS:
-1.5071
Net Cash Flow:
$-124.53M
1W Performance:
-3.90%
1M Performance:
+34.91%
6M Performance:
+57.91%
1Y Performance:
+185.24%
1-Day Range:
Value
$17.56
$18.61
1-Week Range:
Value
$17.38
$19.15
52-Week Range:
Value
$6.135
$19.15

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
Name
Amylyx Pharmaceuticals Inc
Name
Phone
617-682-0917
Name
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Name
Employee
136
Name
Twitter
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
AMLX's Discussions on Twitter

Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AMLX icon
AMLX
Amylyx Pharmaceuticals Inc
17.97 2.00B -665.00K -150.11M -124.53M -1.5071
TAK icon
TAK
Takeda Pharmaceutical Co Adr
16.89 50.65B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
9.72 41.09B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
35.29 39.45B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
75.42 30.13B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
547.25 23.00B 3.17B 1.29B 1.01B 27.09

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-03-26 Initiated Stifel Buy
Jul-10-25 Resumed Goldman Buy
Jun-24-25 Initiated Guggenheim Buy
Jun-17-25 Initiated Citigroup Buy
May-30-25 Initiated TD Cowen Buy
Apr-07-25 Upgrade Mizuho Neutral → Outperform
Nov-18-24 Upgrade Robert W. Baird Neutral → Outperform
Oct-23-24 Upgrade BofA Securities Neutral → Buy
Mar-18-24 Downgrade Mizuho Buy → Neutral
Mar-11-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-11-24 Downgrade Robert W. Baird Outperform → Neutral
Mar-08-24 Downgrade Evercore ISI Outperform → In-line
Mar-08-24 Downgrade Goldman Buy → Neutral
Jan-03-24 Initiated Robert W. Baird Outperform
Dec-12-23 Initiated Deutsche Bank Buy
Jul-24-23 Upgrade Goldman Neutral → Buy
Mar-31-23 Initiated Mizuho Buy
Jan-05-23 Initiated BofA Securities Buy
May-25-22 Initiated Citigroup Buy
Apr-01-22 Downgrade Goldman Buy → Neutral
View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

pulisher
Jun 30, 2026

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey

Jun 30, 2026
pulisher
Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey

Jun 28, 2026
pulisher
Jun 27, 2026

Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today

Jun 27, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jun 26, 2026
pulisher
Jun 26, 2026

Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

AMLX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa

Jun 25, 2026
pulisher
Jun 25, 2026

AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa

Jun 25, 2026
pulisher
Jun 25, 2026

Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK

Jun 25, 2026
pulisher
Jun 25, 2026

Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com

Jun 25, 2026
pulisher
Jun 25, 2026

Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40 - Moomoo

Jun 25, 2026
pulisher
Jun 24, 2026

H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo

Jun 24, 2026
pulisher
Jun 24, 2026

Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 24, 2026
pulisher
Jun 23, 2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 - BioSpace

Jun 23, 2026
pulisher
Jun 23, 2026

Amylyx presents early safety data for ALS drug candidate AMX0114 By Investing.com - Investing.com Nigeria

Jun 23, 2026
pulisher
Jun 23, 2026

Amylyx presents early safety data for ALS drug candidate AMX0114 - Investing.com

Jun 23, 2026
pulisher
Jun 23, 2026

Amylyx says ALS drug AMX0114 showed no serious safety issues - Stock Titan

Jun 23, 2026
pulisher
Jun 23, 2026

Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 23, 2026
pulisher
Jun 22, 2026

AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz

Jun 22, 2026
pulisher
Jun 20, 2026

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Firestone Karen - Moomoo

Jun 20, 2026
pulisher
Jun 20, 2026

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MILNE GEORGE M JR - Moomoo

Jun 20, 2026
pulisher
Jun 18, 2026

Goldman Sachs Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $23 - Moomoo

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 17, 2026

Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 13, 2026

Amylyx Pharmaceuticals eyes Q3 phase 3 Avexitide readout as PBH launch plans take shape - MSN

Jun 13, 2026
pulisher
Jun 12, 2026

How Amylyx’s Class Action Settlement and Phase 3 Avexitide Milestone At Amylyx Pharmaceuticals (AMLX) Has Changed Its Investment Story - simplywall.st

Jun 12, 2026
pulisher
Jun 10, 2026

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape - Yahoo Finance

Jun 10, 2026
pulisher
Jun 09, 2026

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026 - BioSpace

Jun 09, 2026
pulisher
Jun 08, 2026

Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Amylyx (NASDAQ: AMLX) director receives 24,372-share stock option grant - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options - Stock Titan

Jun 08, 2026
pulisher
Jun 08, 2026

Claim your share of the $6.5M Amylyx Pharmaceuticals securities class action settlement - Claim Depot

Jun 08, 2026

Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Klee Justin B.
Co-Chief Executive Officer
Mar 02 '26
Sale
14.47
29,282
423,760
3,334,616
Cohen Joshua B
Co-Chief Executive Officer
Mar 02 '26
Sale
14.48
29,282
424,120
3,334,683
Bedrosian Camille L
Chief Medical Officer
Mar 02 '26
Sale
14.58
6,461
94,205
169,295
FRATES JAMES M
Chief Financial Officer
Mar 02 '26
Sale
14.52
7,909
114,851
165,638
Mazzariello Gina
Chief Legal Officer
Mar 02 '26
Sale
14.52
6,844
99,378
134,430
$55.14
price up icon 1.03%
RDY RDY
$14.36
price down icon 0.14%
$25.13
price up icon 0.52%
$174.10
price down icon 0.09%
$16.80
price up icon 0.60%
$547.25
price down icon 1.56%
Cap:     |  Volume (24h):